Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.
Actively Recruiting
Autosomal Dominant Polycystic Kidney Disease ADPKD is a common genetic kidney condition where fluid-filled cysts develop in the kidneys. This Phase 2 study is evaluating the safety and effectiveness of an investigational drug called ABBV-CLS-628 for adults with ADPKD. The trial aims to understand how this treatment affects kidney volume and kidney function compared to placebo. Participants are randomly assigned to one of four groups three receive different doses of ABBV-CLS-628, and one receives a placebo. Each participant gets an intravenous infusion every 4 weeks for 92 weeks. After this treatment period, participants will be followed for up to 15 additional weeks to monitor their health and any effects. During the study, participants will attend regular visits to a hospital or clinic. Researchers will perform medical assessments, blood tests, and monitor for side effects. Questionnaires will also be completed to gather information. The main outcomes measured include changes in total kidney volume and kidney function, as well as tracking any adverse events over about 118 weeks total.
Actively Recruiting
This trial investigates the use of ivonescimab compared to pembrolizumab as first-line treatments for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. The study focuses on evaluating overall survival and progression-free survival, aiming to understand how these treatments affect disease outcomes in this specific group. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab as intravenous injections. Both treatments are administered as part of a double-blinded, phase 3 study, with a treatment period that may continue while monitoring the patients response and survival for up to approximately 36 months. Throughout the study, participants will undergo regular assessments including measurements of survival, disease progression, response rates, and monitoring for adverse events and laboratory abnormalities. Researchers will collect data on the duration of response and disease control, with safety follow-up continuing up to 30 to 90 days after the last treatment dose or initiation of other anticancer therapies. The overall study period extends until June 2029.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
Researchers are conducting a large, multi-country observational study called LIVER-R to collect real-world data on patients with hepatobiliary cancers, including unresectable hepatocellular carcinoma uHCC, advanced biliary tract cancer aBTC, and other related liver cancers. The study aims to evaluate the effectiveness of treatment regimens that include durvalumab-based therapies or other approaches used in routine clinical practice or early access programs. The study is descriptive and will analyze survival as well as other important clinical outcomes over time. Participants will be observed during their regular clinical care, with data collected both prospectively during visits and retrospectively from medical records, covering a baseline period of up to 5 years before treatment initiation. The study groups include patients receiving durvalumab-based regimens alone or in combination with local regional therapy LRT, as well as those treated with non-durvalumab therapies. Follow-up will continue for at least 2 years or until death, loss to follow-up, withdrawal, or study end. Throughout the study, researchers will gather information on survival rates, treatment duration, progression, recurrence, liver function, treatment patterns, adverse events requiring medical intervention, and patient and provider characteristics. Data will be collected at enrollment and every six months, with real-world overall survival as the primary measure. This extensive monitoring aims to provide a comprehensive view of treatment outcomes and patient experiences in real-world settings across multiple hepatobiliary cancer types.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of JX10, a thrombolytic drug, compared to a placebo in adults aged 18 to 90 who have experienced an Acute Ischemic Stroke AIS and present for care between 4.5 to 24 hours after stroke onset. The study aims to determine whether JX10 improves functional outcomes measured by the modified Rankin Scale and assess the risk of symptomatic intracranial hemorrhage associated with the treatment. The study has two parts. In Part 1, participants are randomly assigned to receive either JX10 at two different doses 1 mgkg or 3 mgkg or a placebo. In Part 2, participants receive either the optimal dose of JX10 selected from Part 1 or placebo. The study is double-blind and randomized to ensure unbiased results. Participants will be monitored for functional recovery over 90 days, with the primary outcome being the proportion of participants with no or minimal symptoms at 90 days post-treatment. Safety is tracked by recording incidence of symptomatic intracranial hemorrhage within 36 hours after randomization and adverse events throughout the study. Secondary measures include functional independence, ordinal Rankin scores, and incidence of major bleeding. The total duration of participation spans at least 90 days following treatment.
Actively Recruiting
This research aims to observe and evaluate the use of the SELUTION SLRTM sirolimus-coated balloon device in treating patients with coronary artery disease, including native vessel lesions and in-stent restenosis. It is a post-market, prospective, multicenter, international, observational study without a control group, focusing on real-world patients to assess the devices safety and effectiveness in everyday clinical practice. Participants receive treatment with the SELUTION SLRTM device as decided by their treating physician. The study monitors patients who have undergone this procedure in various clinical settings, including native coronary artery stenosis and coronary restenosis. This study does not include a comparator group and follows patients longitudinally after treatment. During participation, patients are followed up for at least 12 months to assess major adverse cardiovascular events, such as death, non-fatal heart attacks, and the need for further procedures on the treated lesions. Researchers evaluate both device-oriented and patient-oriented composite endpoints. The study collects data on treatment success shortly after the procedure and monitors safety and effectiveness outcomes over the year following treatment.
Actively Recruiting
Researchers are evaluating a new ultrasound-guided radiofrequency ablation RFA method for treating long-term knee pain caused by joint damage, specifically moderate to severe osteoarthritis. This study focuses on a novel targeting protocol for the genicular nerves around the knee, based on recent anatomical research to improve accuracy and consistency in nerve localization. The aim is to see if this new approach can safely reduce pain and improve movement for people who have not found relief from medicines, physical therapy, or joint injections. Participants will receive a single-session ultrasound-guided thermal RFA treatment targeting three specific genicular nerve branches around the knee. The procedure uses local anesthesia and involves inserting radiofrequency needles under ultrasound guidance. Sensory and motor stimulations confirm correct needle placement before applying heat at 85C for 90 seconds at each site. This approach avoids fluoroscopy and follows updated anatomical landmarks to enhance precision. The treatment session is one-time, with follow-up scheduled for two years. During the study, participants will complete questionnaires about their knee pain and function before treatment and multiple times afterward. Researchers will monitor changes in pain intensity, physical function, and any side effects, including a phone call one week after the procedure to check for any adverse events. The primary outcome is pain change at three months, with additional assessments extending up to two years. The study is free to join, voluntary, and all personal information is kept confidential.
Actively Recruiting
Idiopathic Pulmonary Fibrosis IPF is a rare, chronic lung disease that causes scarring of lung tissue, resulting in shortness of breath and reduced lung function. This platform study evaluates various treatments for IPF, including the investigational drug ABBV-142. The study aims to assess the safety, tolerability, and effectiveness of these treatments in adults with IPF using a master protocol that allows adding or closing substudies over time. Participants will be randomly assigned to receive either ABBV-142 or a matching placebo in a double-blind manner for 52 weeks during the initial treatment phase. Those who qualify may then receive ABBV-142 for an additional 52 weeks in an open-label extension. This design helps compare the investigational drug with placebo and further monitors participants over an extended period. Throughout the study, participants will attend regular visits at hospitals or clinics where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted. Researchers will measure lung function changes, adverse events, and quality of life impacts. After treatment, participants will be followed for 120 days to monitor their health and study outcomes.